Cambridge, MA-based, leading genome editing biotech company, Editas Medicine, recently announced encouraging clinical data in the world's first attempt to use the CRISPR gene editing tool to treat blindness.

Preliminary results from the open-label Phase1/2 BRILLIANCE clinical trial of its investigational CRISPR-based experimental medicine, EDIT-101, have rekindled hope for the patients suffering from blindness due to Leber congenital amaurosis 10 (LCA10).

The safety and efficacy assessments were presented at the XIXth International Symposium on Retinal Degeneration (RD2021) on September 29th.